Quantum-Si’s Post

Introduce more specificity, greater sensitivity and better method performance into your bioanalytical projects. Developed in collaboration with our colleagues of B2S Life Sciences, our new innovative workflow allows for preclinical quantitation of monoclonal antibodies (mAbs) and antibody drug conjugates (ADCs). Download our paper today, and let's talk about how we can help drastically increase your bioanalysis lead times. https://lnkd.in/eE_xApGv #Bioanalysis #LCMS #GLP #AntibodyDrugConjugates #MonoclonalAntibodies

Going to NBC? Be sure to check out Vera Bretton’s poster on Analytical Method Validation Strategy for Determination of Charge Heterogeneity of Antibody Therapeutics Using Reference Material Comparison as an Alternative to Spiking Studies. Learn more about our Antibody Analytical Capabilities here: https://lnkd.in/eQDcApdC #BioA, #Prolytix, #AAPS

If you are attending the National Biotechnology Conference next month in San Fran, be sure to check out Vera Bretton's poster on Analytical Method Validation Strategy for Determination of Charge Heterogeneity of Antibody Therapeutics Using Reference Material Comparison. Vera's expertise helps many clients navigate the research and development hurdles for biologics. Check out the link below to learn more about some of the projects her team supports here at Prolytix!

Yes we do large molecule #bioanalysis at Veloxity Labs, LLC ! The best of both worlds. LC-MS and mAb experts at Veloxity Labs, LLC and B2S Life Sciences, respectively. Coming together to "treat disease, one sample at a time". And...get accustomed to the speed of LC-MS (development data in days not months) and the selectivity of immunoassays all with the expertise of #collaboration Reach out to (Michelle) Shelly Robbins or Callie Celichowski to discuss your #bioanalytical project. #cro #speed #movingatthespeedofbioanalysis

ICYMI: We’re looking for researchers across academia and industry to propose to our new Hermes effort to streamline delivery modalities for #biologic #therapeutics. Efforts to develop novel biologic therapeutics have provided critical resources to enable warfighter readiness and counter existing and emerging biothreats; however, current delivery modalities limit biologics’ efficacy and rapid deployment. The goal of DARPA’s new Hermes program is to overcome the challenges associated with broad, intracellular delivery of biologics to diverse cell and tissue types by developing new delivery modalities that provide systemic distribution with limited negative side effects. A draft Broad Agency Announcement is now available: https://lnkd.in/e2MJexjd

🔬 Novel #Payloads in the ADC Space! 🔬 As we've seen disclosures of several novel payloads within the #ADC space, we've taken this opportunity to highlight some of them: -           EBET-1055 (BET protein degrader): Eisai US and KAN Research Institute -           PRT3789 (SMARCA2 degrader): Prelude Therapeutics and AbCellera -           RIPK2 (PROTAC degraders): GSK & University of Strathclyde -           CBLB inhibitor: Orum Therapeutics -           MYX2339 (NMT inhibitors): Myricx Bio -           PH1 (RNA polymerase II inhibitor): Akari Therapeutics, Plc and Peak Bio Inc. -           CLYP-71 (Lytic peptides): A28 Therapeutics Below is a breakdown of additional ADCs with novel Mechanisms of Action (#MoAs). Have also included a sample of our landscape review of preclinical ADCs here: https://lnkd.in/ev4B6tjc #Oncology #TargetedTherapy #Antibodies #preclinicaldevelopment #innovation #biopharma #linkers

A beacon of precision in the dynamic world of biologics, STAT3 Monoclonal Antibody has been placed. Our STAT3 Monoclonal Antibody stands as a testament to innovation, designed to revolutionize therapeutic approaches by precisely targeting key signaling pathways. Elevate your research and therapeutic strategies with the unparalleled specificity and efficacy of our major discovery antibody. Excited to backpack on the transformative journey with GeNext Genomics, where breakthroughs become a reality. Explore the limitless potential of the STAT3 Monoclonal Antibody and witness the future of precision medicine unfold. . To Read More - https://lnkd.in/gXAd9Ace #GeNextGenomics #HighQualityBiologics #MonoclonalAntibody #STAT3Antibody #PrecisionMedicine 

Difficult-to-express proteins often encounter challenges such as low expression levels, growth inhibition in host cells, and instability in engineered cell lines like CHO cells during passage. To address these challenges, Canton Biologics has developed the DTEasy Toolbox 🔬—a comprehensive solution designed to optimize and integrate the critical stages of the expression process for difficult-to-express proteins. Through molecular design, host selection, DTE vector optimization, and proprietary processes, the DTEasy Toolbox significantly enhances protein yield, thereby facilitating the successful commercialization of protein therapeutics. 📮 Contact us：[email protected] #BiotechInnovation #DTEasyPlatform #ProteinExpression 

Read our latest #EurekaBlog: 'Adventures in FAB Protein Purification'. A Faster single-step platform for expressing antibody fragments is helping to speed up development of #antibody therapeutics. https://okt.to/2gL1dE

Delighted to announce the publication of our review paper in the Journal of Trends in Biotechnology, titled "Membrane technology for the purification of RNA and DNA therapeutics." This review paper provides a detailed examination of the current state and advancements in membrane technologies used for purifying nucleic acids. It focuses on the various methods and efficiencies of these membrane processes, discussing the challenges and future prospects in the field. The paper aims to offer comprehensive insights into the role of membrane technology in the production of RNA and DNA-based therapeutics, highlighting its significance in advancing biopharmaceuticals. I am grateful to my colleague, Kevork Oliver Messerian, and my advisor, Andrew Zydney for their invaluable contributions to our recent publication on membrane technology for RNA and DNA therapeutics. This work was supported by a contract from the US FDA, contract number 75F40122C00200. Read the full paper here: https://lnkd.in/guUmnTkt You have 50 days of free access to the article- until March 01, 2024- using the following link: https://lnkd.in/gAJ85jfT #Biopharmaceuticals #Bioprocessing #Downstreamprocessing #mRNA #DNA #Purification #Concentration #MembraneTechnology #Ultrafiltration